Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Shares Issued (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Shares Issued for 10 consecutive years, with $100.0 as the latest value for Q2 2025.

  • On a quarterly basis, Shares Issued rose 100.82% to $100.0 in Q2 2025 year-over-year; TTM through Sep 2025 was $14.9 million, a 35327.98% increase, with the full-year FY2024 number at $14.9 million, up 16400.5% from a year prior.
  • Shares Issued was $100.0 for Q2 2025 at Marker Therapeutics, down from $505.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $52.7 million in Q1 2021 to a low of -$52.7 million in Q2 2021.
  • A 5-year average of $1.3 million and a median of $27115.5 in 2023 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: skyrocketed 289914.66% in 2024, then tumbled 98.97% in 2025.
  • Marker Therapeutics' Shares Issued stood at -$52.7 million in 2021, then surged by 100.26% to $138557.0 in 2022, then tumbled by 96.29% to $5135.0 in 2023, then surged by 289914.66% to $14.9 million in 2024, then crashed by 100.0% to $100.0 in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Shares Issued are $100.0 (Q2 2025), $505.0 (Q1 2025), and $14.9 million (Q4 2024).